| Multiple Myeloma

Mozobil vs Tecvayli

Side-by-side clinical, coverage, and cost comparison for multiple myeloma.

Deep comparison between: Mozobil vs Tecvayli with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTecvayli has a higher rate of injection site reactions vs Mozobil based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tecvayli but not Mozobil, including UnitedHealthcare

Category

Mozobil

Tecvayli

At A Glance

RouteSC injection

FrequencyOnce daily for up to 4 days

ClassCXCR4 antagonist

RouteSC injection

FrequencyWeekly to every 4 weeks

ClassBCMA-directed CD3 T-cell engager

Indications

Lymphoma, Non-Hodgkin
Multiple Myeloma

Multiple Myeloma

Dosing

Lymphoma, Non-Hodgkin, Multiple Myeloma 0.24 mg/kg SC (or 20 mg fixed dose for patients <=83 kg) once daily approximately 11 hours prior to apheresis for up to 4 consecutive days, following filgrastim 10 mcg/kg once daily for 4 days; maximum 40 mg/day.

Renal Impairment (CrCl <=50 mL/min) Reduce dose by one-third to 0.16 mg/kg SC (or 13 mg fixed dose for patients <=83 kg); maximum 27 mg/day.

Multiple Myeloma (combination with daratumumab and hyaluronidase-fihj) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 3), then 1.5 mg/kg once weekly (weeks 2-8), 3 mg/kg every 2 weeks (weeks 9-24), and 3 mg/kg every 4 weeks (week 25 onward); administer until disease progression or unacceptable toxicity.

Multiple Myeloma (monotherapy) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 4), then 1.5 mg/kg once weekly; may reduce to 1.5 mg/kg every 2 weeks for patients with complete response or better maintained for at least 6 months.

Contraindications

History of hypersensitivity to plerixafor

—

Drug Interactions

500View drug interactions

27View drug interactions

Adverse Reactions

Most common (>=10%) Diarrhea, nausea, injection site reactions, fatigue, headache, arthralgia, dizziness, vomiting

Serious Anaphylactic shock, hypersensitivity reactions, tumor cell mobilization, hyperleukocytosis, decreased platelet counts, splenic enlargement

Postmarketing Splenomegaly, splenic rupture, anaphylactic reactions including anaphylactic shock, abnormal dreams and nightmares

Most common (>=20%) pyrexia, cytokine release syndrome, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, diarrhea, hypogammaglobulinemia, cough, COVID-19, gastroenteritis, weight decreased

Serious pneumonia, cytokine release syndrome, sepsis, pyrexia, COVID-19, febrile neutropenia, gastroenteritis, acute kidney injury, encephalopathy, second primary malignancy

Pharmacology

Plerixafor is a CXCR4 chemokine receptor inhibitor that blocks binding of stromal cell-derived factor-1alpha (SDF-1alpha), disrupting HSC anchoring in the bone marrow and mobilizing hematopoietic stem cells to the peripheral blood for apheresis collection.

Teclistamab-cqyv is a bispecific T-cell engaging antibody that binds CD3 on T-cells and BCMA on multiple myeloma cells, activating T-cells to release proinflammatory cytokines and lyse myeloma cells.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Mozobil